BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29955851)

  • 1. Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.
    Venkatesan S; Carias C; Biggerstaff M; Campbell AP; Nguyen-Van-Tam JS; Kahn E; Myles PR; Meltzer MI
    J Public Health (Oxf); 2019 Jun; 41(2):379-390. PubMed ID: 29955851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
    Pasquini-Descomps H; Brender N; Maradan D
    Value Health; 2017 Jun; 20(6):819-827. PubMed ID: 28577700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
    Lee VJ; Phua KH; Chenm MI; Chow A; Ma S; Goh KT; Leo YS
    Emerg Infect Dis; 2006 Jan; 12(1):95-102. PubMed ID: 16494724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis.
    Milne GJ; Halder N; Kelso JK
    PLoS One; 2013; 8(4):e61504. PubMed ID: 23585906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
    Moss R; McCaw JM; Cheng AC; Hurt AC; McVernon J
    BMC Infect Dis; 2016 Oct; 16(1):552. PubMed ID: 27724915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.
    Kamal MA; Smith PF; Chaiyakunapruk N; Wu DBC; Pratoomsoot C; Lee KKC; Chong HY; Nelson RE; Nieforth K; Dall G; Toovey S; Kong DCM; Kamauu A; Kirkpatrick CM; Rayner CR
    Br J Clin Pharmacol; 2017 Jul; 83(7):1580-1594. PubMed ID: 28176362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic.
    O'Hagan JJ; Wong KK; Campbell AP; Patel A; Swerdlow DL; Fry AM; Koonin LM; Meltzer MI
    Clin Infect Dis; 2015 May; 60 Suppl 1(0 1):S30-41. PubMed ID: 25878299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009.
    Doshi S; Kamimoto L; Finelli L; Perez A; Reingold A; Gershman K; Yousey-Hindes K; Arnold K; Ryan P; Lynfield R; Morin C; Baumbach J; Hancock EB; Bennett NM; Zansky S; Thomas A; Schaffner W; Fry AM
    J Infect Dis; 2011 Dec; 204(12):1848-56. PubMed ID: 22013219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
    Lugnér AK; Postma MJ
    Eur J Public Health; 2009 Oct; 19(5):516-20. PubMed ID: 19692550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada.
    Coleman BL; Hassan K; Green K; Gubbay JB; Katz K; Mazzulli T; McNeil S; Muller M; Powis J; Richardson D; Simor A; ; McGeer AJ
    Antiviral Res; 2017 Apr; 140():158-163. PubMed ID: 28179155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain.
    Canadell L; Martín-Loeches I; Díaz E; Trefler S; Grau S; Yebenes JC; Almirall J; Olona M; Sureda F; Blanquer J; Rodriguez A;
    Med Intensiva; 2015 May; 39(4):222-33. PubMed ID: 25107582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
    Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
    Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States.
    Atkins CY; Patel A; Taylor TH; Biggerstaff M; Merlin TL; Dulin SM; Erickson BA; Borse RH; Hunkler R; Meltzer MI
    Emerg Infect Dis; 2011 Sep; 17(9):1591-8. PubMed ID: 21888783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.
    Postma MJ; Novak A; Scheijbeler HW; Gyldmark M; van Genugten ML; Wilschut JC
    Pharmacoeconomics; 2007; 25(6):497-509. PubMed ID: 17523754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we prepared for the next influenza pandemic? Lessons from modelling different preparedness policies against four pandemic scenarios.
    Panovska-Griffiths J; Grieco L; van Leeuwen E; Baguelin M; Pebody R; Utley M
    J Theor Biol; 2019 Nov; 481():223-232. PubMed ID: 31059716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
    O'Brien BJ; Goeree R; Blackhouse G; Smieja M; Loeb M
    Value Health; 2003; 6(2):116-25. PubMed ID: 12641862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
    Shen K; Xiong T; Tan SC; Wu J
    PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia.
    Lee N; Chan PK; Wong CK; Wong KT; Choi KW; Joynt GM; Lam P; Chan MC; Wong BC; Lui GC; Sin WW; Wong RY; Lam WY; Yeung AC; Leung TF; So HY; Yu AW; Sung JJ; Hui DS
    Antivir Ther; 2011; 16(2):237-47. PubMed ID: 21447873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential for multidrug-resistant influenza.
    van der Vries E; Schutten M; Boucher CA
    Curr Opin Infect Dis; 2011 Dec; 24(6):599-604. PubMed ID: 22001947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.